Biocon
M. Damodaran is a Non-Executive, Independent Director at Biocon. M. was previously with Vedanta Resources Plc from July 2009 to April 2016, where they served as Associate Manager - Power Plant. In this role, they were responsible for helping the users resolve issues faced in the purchase cycle, such as PR, PO, GRN, and Service entry. M. also initiated modifications, such as implementing a new PR release strategy with Characteristic and class assignment. In addition, they worked with the ABAP Consultant to develop the workflow cycle for PR Release. As a MM CTM, they worked on SAP GRC for assigning authorizations to the users. M. has also done configuration in SPRO for Creating Storage location, Creating new release strategy, activating different views for material master, Assigning Field selection values to all the fields in PR, assigning no. ranges to PR/PO, and Allowing Doc. Type assignment from PR to PO. Damodaran is adept in managing resource planning, in process inspection, team building and co-ordination with internal/external departments. M. is also instrumental in Project execution, commissioning and instrumentation maintenance of captive power plant . M. has experience with implementing Integrated Management System and is a certified internal auditor of ISO 9001,ISO 14001 and OHSAS 18001.
M. Damodaran's educational career began with a B.E in Electronics and Instrumentation from Government College of Technology. M. then went on to earn a certification from LinkedIn in Learning Data Analytics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.